OBJECTIVE: To investigate the presence of possible early atherosclerotic changes in a group of prepubertal children with juvenile idiopathic arthritis (JIA) and to establish the potential beneficial effects of 1-year treatment. MATERIALS AND METHODS: Inflammatory markers (C-reactive protein, erythrocyte sedimentation rate), proinflammatory cytokines (IL-1β, IL-6, IFN-γ, TNF-α), lipid profile and oxidant-antioxidant status (urinary isoprostanes [PGF-2α]) were assessed in 38 JIA children (12M/26F, mean age 7.05 ± 2.39 years) and compared with 40 controls (18M/22F, mean age 6.34 ± 2.25 years). Carotid intima-media wall thickness (cIMT) was obtained and blood pressure was measured. All parameters were reassessed in JIA children after 1 year of therapy. RESULTS: At baseline JIA children presented compared to controls higher levels of inflammatory markers, proinflammatory cytokines, total cholesterol, LDL cholesterol, and PGF-2α (all p ≤ 0.01). Furthermore, blood pressure and cIMT were significantly increased (both p ≤ 0.01). After a 1-year treatment with non-steroid anti-inflammatory (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs), a significant reduction of all parameters was detected (all p ≤ 0.01). This was associated with a significant reduction in blood pressure and cIMT (both p ≤ 0.01). Within the JIA group, patients requiring etanercept presented worse laboratory values and cIMT measurements at baseline. Nevertheless, the same improvement of all parameters was obtained after a 1-year treatment. In stepwise multiple regression, LDL cholesterol and IL-1β were mainly related to cIMT. CONCLUSION: Chronic and systemic inflammation seems to lead to early atherosclerotic abnormalities even in pre-pubertal JIA children. Substantial improvement can be obtained with 1-year of appropriate therapy.
OBJECTIVE: To investigate the presence of possible early atherosclerotic changes in a group of prepubertal children with juvenile idiopathic arthritis (JIA) and to establish the potential beneficial effects of 1-year treatment. MATERIALS AND METHODS: Inflammatory markers (C-reactive protein, erythrocyte sedimentation rate), proinflammatory cytokines (IL-1β, IL-6, IFN-γ, TNF-α), lipid profile and oxidant-antioxidant status (urinary isoprostanes [PGF-2α]) were assessed in 38 JIA children (12M/26F, mean age 7.05 ± 2.39 years) and compared with 40 controls (18M/22F, mean age 6.34 ± 2.25 years). Carotid intima-media wall thickness (cIMT) was obtained and blood pressure was measured. All parameters were reassessed in JIA children after 1 year of therapy. RESULTS: At baseline JIA children presented compared to controls higher levels of inflammatory markers, proinflammatory cytokines, total cholesterol, LDL cholesterol, and PGF-2α (all p ≤ 0.01). Furthermore, blood pressure and cIMT were significantly increased (both p ≤ 0.01). After a 1-year treatment with non-steroid anti-inflammatory (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs), a significant reduction of all parameters was detected (all p ≤ 0.01). This was associated with a significant reduction in blood pressure and cIMT (both p ≤ 0.01). Within the JIA group, patients requiring etanercept presented worse laboratory values and cIMT measurements at baseline. Nevertheless, the same improvement of all parameters was obtained after a 1-year treatment. In stepwise multiple regression, LDL cholesterol and IL-1β were mainly related to cIMT. CONCLUSION: Chronic and systemic inflammation seems to lead to early atherosclerotic abnormalities even in pre-pubertal JIA children. Substantial improvement can be obtained with 1-year of appropriate therapy.
Authors: Lennart T H Jacobsson; Carl Turesson; Anders Gülfe; Meliha C Kapetanovic; Ingemar F Petersson; Tore Saxne; Pierre Geborek Journal: J Rheumatol Date: 2005-07 Impact factor: 4.666
Authors: Carlos Gonzalez-Juanatey; Javier Llorca; Javier Martin; Miguel A Gonzalez-Gay Journal: Semin Arthritis Rheum Date: 2008-03-12 Impact factor: 5.532
Authors: Carlos Gonzalez-Juanatey; Javier Llorca; Encarnacion Amigo-Diaz; Trinidad Dierssen; Javier Martin; Miguel A Gonzalez-Gay Journal: Arthritis Rheum Date: 2007-08-15
Authors: Camila Pugliese; Roberta T A van der Vinne; Lucia M A Campos; Priscila R Guardieiro; Cynthia Saviolli; Eloisa Bonfá; Rosa M R Pereira; Vilma S Viana; Eduardo F Borba; Clovis A Silva Journal: Clin Rheumatol Date: 2015-12-01 Impact factor: 2.980
Authors: Christoph Sinning; Arne Kieback; Philipp S Wild; Renate B Schnabel; Francisco Ojeda; Sebastian Appelbaum; Tanja Zeller; Edith Lubos; Edzard Schwedhelm; Karl J Lackner; Eike S Debus; Thomas Munzel; Stefan Blankenberg; Christine Espinola-Klein Journal: Clin Res Cardiol Date: 2014-02-02 Impact factor: 5.460
Authors: J H Anderson; K R Anderson; H A Aulie; C S Crowson; T G Mason; S P Ardoin; A M Reed; B Flatø Journal: Scand J Rheumatol Date: 2016-02-08 Impact factor: 3.641
Authors: Oliver Dörr; Christoph Liebetrau; Helge Möllmann; Felix Mahfoud; Sebastian Ewen; Luise Gaede; Christian Troidl; Jedrzej Hoffmann; Nikolai Busch; Gerald Laux; Jens Wiebe; Timm Bauer; Christian Hamm; Holger Nef Journal: Clin Res Cardiol Date: 2014-10-18 Impact factor: 5.460
Authors: Emanuela Del Giudice; Anna Dilillo; Luciana Tromba; Giuseppe La Torre; Sara Blasi; Fabrizio Conti; Franca Viola; Salvatore Cucchiara; Marzia Duse Journal: Clin Rheumatol Date: 2017-10-12 Impact factor: 2.980
Authors: Jaanika Ilisson; Maksim Zagura; Kersti Zilmer; Erik Salum; Kaire Heilman; Anneli Piir; Vallo Tillmann; Jaak Kals; Mihkel Zilmer; Chris Pruunsild Journal: Arthritis Res Ther Date: 2015-07-16 Impact factor: 5.156
Authors: Anna-Helene Bohr; Robert C Fuhlbrigge; Freddy Karup Pedersen; Sarah D de Ferranti; Klaus Müller Journal: Pediatr Rheumatol Online J Date: 2016-01-06 Impact factor: 3.054